Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 16/20 | 0.58 |
| ▸ | PRKDC | P78527 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | TLR2 | O60603 | 1/20 | 0.45 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.45 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24140773 | 0.84 | ERN1 (0.64) | ERN1PRKDCKDM4EALDH1A1TSHR | |
| SCHEMBL7966625 | 0.84 | ERN1 (0.64) | ERN1PRKDCKDM4EALDH1A1TSHR | |
| SCHEMBL1646879 | 0.84 | ERN1 (0.64) | ERN1PRKDCKDM4EALDH1A1TSHR | |
| SCHEMBL15534494 | 0.81 | ERN1 (0.73) | ERN1PRKDCKDM4EALDH1A1TSHR | |
| SCHEMBL23094539 | 0.81 | ERN1 (0.60) | ERN1PRKDCKDM4EALDH1A1TSHR | |
| SCHEMBL9861378 | 0.81 | ERN1 (0.60) | ERN1PRKDCKDM4EALDH1A1TSHR | |
| SCHEMBL9016756 | 0.81 | PRKDC (0.53) | ERN1PRKDCKDM4EALDH1A1TSHR | |
| SCHEMBL9860690 | 0.78 | ERN1 (0.57) | ERN1PRKDCKDM4EALDH1A1TSHR | |
| SCHEMBL24984316 | 0.78 | ERN1 (0.55) | ERN1KDM4EALDH1A1TSHRTDP1 | |
| SCHEMBL17263377 | 0.76 | ERN1 (0.54) | ERN1KDM4EALDH1A1TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10947206-B2 | cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| EP-0481441-B1 | Novel cephem compounds, their preparation processes and antibacterial agents | KYORIN SEIYAKU KK (JP) | 1996-12-11 | — | — | EP | disclosed |
| US-5244892-A | Pseudomonas | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1993-09-14 | — | — | US | disclosed |
| EP-0481441-A2 | Novel cephem compounds, their preparation processes and antibacterial agents | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1992-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10947206-B2 | cGAS antagonist compounds | CGAS, STING1, GLS2 | ERN1 2251/4885PRKDC 1829/4885KDM4E 4717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.